pramipexole immediate release (CTC-501) / Chase Therap - LARVOL DELTA

A Study in Patients With Major Depressive Disorder (clinicaltrials.gov) - P2 | N=24 | Active, not recruiting | Sponsor: Chase Therapeutics Corporation | Phase classification: P2a ➔ P2 | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Phase classification • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study in Patients With Major Depressive Disorder (clinicaltrials.gov) - P2a | N=24 | Active, not recruiting | Sponsor: Chase Therapeutics Corporation | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2024

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study in Patients With Major Depressive Disorder (clinicaltrials.gov) - P2a | N=24 | Active, not recruiting | Sponsor: Chase Therapeutics Corporation | Trial completion date: May 2021 ➔ Dec 2022

Trial completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Chase Therapeutics Announces $20 Million Series B Financing to Advance Clinical Trials in Parkinson’s Disease and Major Depressive Disorder (Businesswire) - "Chase Therapeutics Corporation...today announced the completion of a milestone-based $20M Series B financing led by Chinalink Asia Holdings of Hong Kong....The proceeds of the Series B will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder (MDD) and CTC-413 for the treatment of Parkinson’s Disease (PD) as well as completion of the development and validation of a diagnostic product for Parkinson’s Disease."

Financing • CNS Disorders • Depression • Major Depressive Disorder • Parkinson's Disease

A Study in Patients With Major Depressive Disorder (clinicaltrials.gov) - P2a; N=24; Active, not recruiting; Sponsor: Chase Therapeutics Corporation; Trial completion date: May 2019 ➔ May 2021; Trial primary completion date: May 2019 ➔ May 2021

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Lactobacillus paraplantarum THG-G10 as a potential anti-acne agent with anti-bacterial and anti-inflammatory activities. (PubMed, Anaerobe) - "Anti-microbial activity was examined by a broth dilution assay: 25 mg/ml of DC-G10 inhibited the growth of C. acnes KCTC 5012 and KACC 1194; salicylic acid and benzoyl peroxide for acne treatment inhibited the growth of C. acnes KCTC 5012 and KACC 11946 at concentrations of 1.25 and 7.5 mg/ml, respectively; and tea tree oil inhibited the growth of C. acnes KCTC 5012 but not the growth of C. acnes KACC 11946 at 50 mg/ml...Furthermore, scanning electron microscopy revealed that DC-G10 induces deleterious morphological changes in the bacterial cell membrane. These results demonstrate that DC-G10 may be an effective and safe treatment for acne vulgaris."

Journal • Acne Vulgaris • Dermatology • Dermatopathology

A panel consisting of three novel circulating lncRNAs, is it a predictive tool for gastric cancer? (PubMed, J Cell Mol Med) - "We identified three lncRNAs, CTC-501O10.1, AC100830.4 and RP11-210K20.5 that were up-regulated in the plasma of GC patients with AUCs 0.724, 0.730 and 0.737, respectively (P < .01)...The AUC of the panel was 0.700 in the validation cohort. These findings indicate that plasma lncRNAs can serve as potential biomarkers for detection of GC."

Biomarker • Journal